Compare
Polomar Health Services, Inc. vs Lexaria Bioscience Corp. vs PMGC Holdings Inc. vs Yarrow Bioscience, Inc.
| Latest fiscal year | Polomar Health Services, Inc. PMHS | Lexaria Bioscience Corp. LEXX | PMGC Holdings Inc. ELAB | Yarrow Bioscience, Inc. YARW |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-08-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $648.2K | $705.9K | $590.1K | $570.0K |
| Revenue growth (YoY) | n/m | +52.0% | n/a | +13.8% |
| Gross margin | 71.0% | 99.6% | 31.4% | n/a |
| Operating margin | n/m | n/m | n/a | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$10.70M | -$11.90M | -$7.75M | -$26.48M |
| EPS (Diluted) | -$0.39 | -$0.66 | n/a | -$0.62 |
| Operating cash flow | -$396.0K | -$10.45M | -$5.93M | -$33.12M |
| Free cash flow | n/a | -$10.48M | -$6.38M | -$33.12M |
| Cash & equivalents | $132.2K | n/a | n/a | $24.03M |
| Total assets | $390.0K | $4.18M | $12.87M | $30.16M |
| Total liabilities | $1.61M | $1.57M | $5.03M | $2.40M |
| Shareholders' equity | -$1.22M | $2.99M | $7.84M | $27.77M |
| Return on year-end equity | n/a | -398.1% | -98.9% | -95.4% |
| Shares outstanding | 28.02M | 19.56M | 80.7K | 33.32M |
Revenue, most recent five fiscal years
| Fiscal year | Polomar Health Services, Inc. | Lexaria Bioscience Corp. | PMGC Holdings Inc. | Yarrow Bioscience, Inc. |
|---|---|---|---|---|
| Latest | $648.2K Ended 2025-12-31 | $705.9K Ended 2025-08-31 | $590.1K Ended 2025-12-31 | $570.0K Ended 2025-12-31 |
| 1 year earlier | $58.8K Ended 2024-12-31 | $464.3K Ended 2024-08-31 | n/a | $501.0K Ended 2024-12-31 |
| 2 years earlier | $41.8K Ended 2023-12-31 | $226.2K Ended 2023-08-31 | $1.71M Ended 2023-12-31 | $424.0K Ended 2023-12-31 |
| 3 years earlier | $34.5K Ended 2022-12-31 | $255.4K Ended 2022-08-31 | $766.3K Ended 2022-12-31 | $477.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $722.7K Ended 2021-08-31 | n/a | $931.0K Ended 2021-12-31 |